Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions SGD. Fiscal year is January - December.

Millions SGD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Aug '25 Aug 13, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	23	20	17	18	15	19	Upgrade
Market Cap Growth	13.93%	13.93%	-5.43%	21.70%	-19.70%	-33.33%	Upgrade
Enterprise Value	17	11	-0	32	19	27	Upgrade
Last Close Price	0.17	0.13	0.12	0.12	0.10	0.13	Upgrade
PE Ratio	5.98	5.03	-	7.25	44.64	-	Upgrade
PS Ratio	0.52	0.44	0.34	0.13	0.25	0.27	Upgrade
PB Ratio	0.35	0.29	0.27	0.28	0.25	0.30	Upgrade
P/TBV Ratio	0.34	0.29	0.26	0.22	0.19	0.24	Upgrade
P/FCF Ratio	-	-	4.35	-	0.77	-	Upgrade
P/OCF Ratio	-	-	4.26	-	0.76	-	Upgrade
EV/Sales Ratio	0.39	0.26	-	0.24	0.33	0.40	Upgrade
EV/EBITDA Ratio	32.58	-	-	4.41	-	-	Upgrade
EV/EBIT Ratio	-	-	-	5.70	-	-	Upgrade
EV/FCF Ratio	-5.82	-	-	-	1.01	-	Upgrade
Debt / Equity Ratio	0.15	0.15	0.16	0.45	0.37	0.60	Upgrade
Debt / EBITDA Ratio	-	-	5.29	3.92	107.65	-	Upgrade
Debt / FCF Ratio	-	-	2.62	-	1.15	-	Upgrade
Asset Turnover	0.48	0.48	0.48	1.11	0.49	0.58	Upgrade
Inventory Turnover	2.83	2.83	2.71	8.83	3.41	4.20	Upgrade
Quick Ratio	1.69	1.69	1.76	1.00	0.94	1.03	Upgrade
Current Ratio	2.42	2.42	2.50	1.80	1.24	1.47	Upgrade
Return on Equity (ROE)	6.09%	6.09%	-2.07%	3.71%	1.03%	-7.27%	Upgrade
Return on Assets (ROA)	-2.18%	-2.18%	0.11%	2.87%	-1.00%	-1.47%	Upgrade
Return on Capital (ROIC)	-2.65%	-2.65%	0.13%	3.94%	-1.34%	-1.75%	Upgrade
Return on Capital Employed (ROCE)	-	-	0.30%	7.90%	-	-	Upgrade
Earnings Yield	16.74%	19.87%	-104.82%	13.80%	2.24%	-27.00%	Upgrade
FCF Yield	-12.89%	-15.30%	22.98%	-58.15%	129.98%	-47.82%	Upgrade
Dividend Yield	2.86%	3.73%	-	-	-	-	Upgrade
Total Shareholder Return	3.14%	3.73%	-	-	-	-	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.